查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1791749

非侵入性幽門螺旋桿菌檢測的全球市場

Non-invasive Helicobacter Pylori Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球非侵入性幽門螺旋桿菌檢測市場規模將達到 4.459 億美元

全球非侵入性幽門螺旋桿菌檢測市場規模預計在2024年為3.163億美元，到2030年預計將達到4.459億美元，在分析期間（2024-2030年）的複合年成長率為5.9%。血清學檢測是本報告分析的細分市場之一，預計其複合年成長率為6.3%，到分析期結束時達到2.509億美元。尿素呼氣檢測市場規模預計在分析期間的複合年成長率為4.8%。

美國市場規模估計為 8,320 萬美元，中國市場預計複合年成長率為 5.8%

美國非侵入性幽門螺旋桿菌檢測市場規模預計在2024年達到8,320萬美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到7,180萬美元，在2024-2030年的分析期內，複合年成長率為5.8%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為5.5%和5.0%。在歐洲，預計德國市場的複合年成長率為4.7%。

全球非侵入性幽門螺旋桿菌檢測市場－主要趨勢與促進因素摘要

為什麼非侵入性檢測成為檢測幽門螺旋桿菌的首選途徑？

全球醫療保健在幽門螺旋桿菌 (H. pylori) 診斷方面正在發生重大轉變，非侵入性檢測方法正迅速取代傳統的侵入性方法。從歷史上看，內視鏡檢查和切片檢查是識別這種胃病原體的黃金標準，但它會帶來很大的不適感、高成本和操作風險，尤其是在無症狀患者和兒科患者中。尿素呼氣試驗 (UBT)、糞便抗原試驗 (SAT) 和血清學試驗等非侵入性檢測由於其簡單、快速和患者友善性，現在已在臨床和商業性廣泛應用。這些檢測無需鎮靜、侵入性樣本採集或醫院程序即可進行有效檢體。尿素呼氣試驗尤其以其高準確性、快速性以及對初步診斷和治療後後續觀察的適用性而脫穎而出。此外，糞便抗原檢測由於其可靠性和易於檢體採集而被廣泛採用，尤其是在小兒科。儘管血清學檢測在根除後監測方面存在局限性，但在資源匱乏、價格可負擔和便捷性至關重要的地區，它們仍被廣泛應用。隨著人們對胃炎、潰瘍和胃癌日益成長的擔憂，全球對胃腸道健康和早期檢測的認知不斷提高，極大地推動了這些非侵入性解決方案的普及。在醫療保健提供者轉向價值導向醫療的時代，非侵入性幽門螺旋桿菌診斷技術將臨床效率與患者依從性完美結合，重新定義了胃腸道疾病管理的標準。

檢測技術的進步如何提高準確性和病患治療效果？

技術進步在提高非侵入性幽門螺旋桿菌診斷的準確性、可及性和可擴展性方面發揮了核心作用。質譜法、免疫測量和標記碳同位素等創新技術顯著提高了尿素呼氣試驗的敏感度和特異性，使臨床醫生能夠非常自信地檢測出活動性性行為感染。同樣，基於單株抗體的糞便抗原檢測的開發也提高了診斷準確性，最大限度地減少了假陰性，即使在低細菌負荷情況下也能提供可靠的結果。近年來，樣品製備、轉運介質和家用檢測套組的進步進一步擴展了這些診斷方法的適用性，使其適用於社區和遠端醫療模式。行動式呼吸檢測裝置和可攜式分析儀也已進入市場，使鄉村診所、難民營和偏遠醫療機構能夠進行現場診斷。此外，將人工智慧主導的分析技術整合到實驗室檢測環境中，簡化了工作流程並支援快速的結果解讀，這對於高通量公共衛生實驗室尤其有用。新興企業正在探索使用非同位素感測器檢測呼氣生物標記物，預計將降低尿素呼吸檢測的成本和複雜性。這些創新不僅提高了診斷質量，還能加速治療決策，降低病情進展風險，並提高患者對後續治療方案的依從性。隨著如今醫院外已有快速、準確的檢測工具，幽門螺旋桿菌檢測有望滿足現代醫療保健對便利、快速和準確的期望。

公共衛生重點和篩檢措施的變化是否會推動市場發展？

公共衛生重點的轉變以及對早期胃腸道篩檢的日益重視，是推動非侵入性幽門螺旋桿菌檢測日益普及的關鍵因素。由於幽門螺旋桿菌與多種胃部疾病（包括消化性潰瘍、慢性胃炎和胃癌）有關，因此早期發現和根除幽門螺旋桿菌是全球衛生策略的重點，尤其是在亞太地區、拉丁美洲和東歐等高發地區。在日本和韓國等國家，國家篩檢計畫已將非侵入性檢測制度化，作為常規預防性篩檢的一部分，從而顯著降低了胃癌發病率。在西方國家，人們日益意識到未經治療的幽門螺旋桿菌病菌感染與長期胃腸道併發症之間的關聯，這促使全科醫生即使在沒有明顯症狀的情況下也建議進行篩檢。 COVID-19 疫情進一步加速了向非侵入性診斷方法的轉變，因為醫療保健系統正在尋求減少門診程序並減輕醫院基礎設施壓力的方法。非侵入性檢測與這些修訂後的通訊協定無縫銜接，支援在家採集樣本和非接觸式就診。此外，醫療保險公司和支付方越來越認知到非侵入性早期檢測的成本效益，並正在擴大呼氣和糞便檢測的報銷範圍。非政府組織和公共衛生機構也正在資助高負擔和服務欠缺地區的低成本檢測舉措，以提高可近性的公平性。隨著這些計畫的推廣和成功，將非侵入性幽門螺旋桿菌檢測作為預防性胃腸道護理基石的理由將變得更加引人注目。

哪些因素推動了非侵入性幽門螺旋桿菌檢測市場的擴張？

非侵入性幽門螺旋桿菌檢測市場的成長受到與技術創新、醫療保健服務趨勢、不斷變化的患者偏好和疾病負擔動態相關的多種因素的驅動。在技術水準，診斷平台的快速進步使基於呼吸和糞便的測試更加可靠和高效，使其適合廣泛的臨床和家庭使用。這些平台擴大與數位健康工具相結合，實現結果追蹤、自動警報以及患者和醫療保健提供者之間的無縫溝通。在臨床方面，對門診護理和早期診斷的日益成長的偏好促使醫生選擇非侵入性方法，以最大限度地降低風險、簡化工作流程並加快治療開始。最終用戶的需求也受到消費者對腸道健康、食源性病原體以及未治療感染疾病的長期風險的認知不斷提高的影響。患者，尤其是年輕族群和那些能夠獲得數位健康資源的患者，正在積極尋求侵入性較小、更方便的檢測選擇。同時，由於衛生條件差、抗生素抗藥性和飲食習慣改變等因素，幽門螺旋桿菌的盛行率不斷上升，這推動了已開發市場和新興市場對可擴展且經濟高效的診斷方法的需求。醫療保健系統面臨著降低成本和改善預防保健指標的壓力，正在投資優先考慮非侵入性解決方案的篩檢項目。最後，有利的監管條件和製藥公司（尤其是銷售用於根除治療的抗生素的公司）的日益參與，正在推動透過將診斷與治療通訊協定捆綁在一起的檢測方法得到廣泛採用。這些綜合因素正在推動全球非侵入性幽門螺旋桿菌檢測市場強勁且持續的成長。

部分

檢測類型（血清學、尿素呼吸檢測、糞便/糞便抗原檢測）；檢測方法（實驗室檢測、即時檢測）；最終使用者（診斷實驗室最終使用者、醫院最終使用者、診所最終使用者、其他最終使用者）

受訪公司範例

  • Abbott Laboratories
  • Biohit Oyj
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Certest Biotec SL
  • Coris Bioconcept SPRL
  • DiaSorin SpA
  • Exalenz Bioscience Ltd.
  • Fujirebio Holdings, Inc.
  • Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Otsuka Holdings Co., Ltd.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Thermo Fisher Scientific Inc.

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP32372

Global Non-invasive Helicobacter Pylori Testing Market to Reach US$445.9 Million by 2030

The global market for Non-invasive Helicobacter Pylori Testing estimated at US$316.3 Million in the year 2024, is expected to reach US$445.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Serologic Test, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$250.9 Million by the end of the analysis period. Growth in the Urea Breath Test segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$83.2 Million While China is Forecast to Grow at 5.8% CAGR

The Non-invasive Helicobacter Pylori Testing market in the U.S. is estimated at US$83.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$71.8 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Non-Invasive Helicobacter Pylori Testing Market - Key Trends & Drivers Summarized

Why Is Non-Invasive Testing Emerging as the Preferred Route for Detecting H. Pylori?

The global healthcare landscape is witnessing a profound shift in the diagnosis of Helicobacter pylori (H. pylori) with non-invasive testing rapidly replacing traditional, invasive approaches. Historically, endoscopy with biopsy was the gold standard for identifying this gastric pathogen, but it came with considerable discomfort, higher costs, and procedural risks-especially for asymptomatic or pediatric patients. Non-invasive tests such as the urea breath test (UBT), stool antigen test (SAT), and serology are now gaining widespread clinical and commercial traction for their simplicity, speed, and patient-friendly nature. These methods allow for efficient detection without sedation, specimen collection through invasive means, or hospital-based procedures. The urea breath test, in particular, stands out due to its high accuracy, rapid turnaround time, and suitability for both initial diagnosis and post-treatment follow-up. Additionally, stool antigen tests have become widely adopted due to their reliability and ease of sample collection, especially in pediatric settings. Serological tests, while limited in post-eradication monitoring, are still widely used in low-resource settings where affordability and accessibility are paramount. The global increase in awareness of gastrointestinal health and early testing-fueled by growing concerns around gastritis, ulcers, and gastric cancers-is significantly propelling the adoption of these non-invasive solutions. In a world where healthcare providers are shifting toward value-based care, non-invasive H. pylori diagnostics offer a powerful blend of clinical efficiency and patient compliance, redefining standards in gastrointestinal disease management.

How Are Advancements in Testing Technology Enhancing Accuracy and Patient Outcomes?

Technological progress has played a central role in elevating the accuracy, accessibility, and scalability of non-invasive H. pylori diagnostics. Innovations in mass spectrometry, immunoassays, and labeled carbon isotopes have considerably improved the sensitivity and specificity of urea breath tests, allowing clinicians to detect active infections with exceptional confidence. Similarly, the development of monoclonal antibody-based stool antigen tests has enhanced diagnostic precision by minimizing false negatives and providing robust results even in low bacterial load scenarios. In recent years, advancements in sample preparation, transport media, and at-home testing kits have further expanded the reach of these diagnostics, making them more suitable for community and telehealth models. Mobile breath testing units and portable analyzers are also entering the market, enabling on-site diagnosis in rural clinics, refugee camps, and remote health settings. Furthermore, the integration of AI-driven analytics in lab-based testing environments is streamlining workflow and supporting quicker result interpretation, which is especially useful in high-throughput public health labs. Some emerging companies are even exploring breath biomarker detection using non-isotopic sensors, potentially reducing the cost and complexity of urea breath testing. Collectively, these innovations are not only raising the bar for diagnostic quality but also enabling faster treatment decisions, lowering disease progression risks, and improving patient adherence to follow-up regimens. With rapid and accurate tools now available outside of hospital walls, H. pylori testing is becoming more aligned with modern healthcare expectations-convenience, speed, and precision.

Are Shifting Public Health Priorities and Screening Initiatives Boosting Market Momentum?

Changing public health priorities and the growing emphasis on early gastrointestinal screening are key contributors to the increasing adoption of non-invasive H. pylori testing. With the bacterium implicated in a wide array of gastric disorders-including peptic ulcers, chronic gastritis, and gastric cancer-early detection and eradication have become focal points in global health strategies, especially in regions with high prevalence rates such as Asia-Pacific, Latin America, and Eastern Europe. National screening programs in countries like Japan and South Korea have already institutionalized non-invasive testing as part of routine preventive health check-ups, leading to measurable reductions in gastric cancer incidence. In Western countries, increased awareness about the link between untreated H. pylori infection and long-term gastrointestinal complications has spurred general practitioners to recommend screening even in the absence of overt symptoms. The COVID-19 pandemic has further accelerated the shift toward non-invasive diagnostics, as healthcare systems sought ways to minimize in-clinic procedures and reduce the burden on hospital infrastructure. Non-invasive tests fit seamlessly into these revised protocols, supporting home-based sample collection and contactless consultations. Additionally, health insurers and payers are increasingly recognizing the cost-effectiveness of early, non-invasive detection, and are extending reimbursement coverage to breath and stool-based tests. Non-governmental organizations and public health agencies are also funding low-cost testing initiatives in high-burden, underserved areas, reinforcing equity in access. As these programs expand and prove successful, the case for non-invasive H. pylori testing as a cornerstone of preventive gastrointestinal care becomes increasingly compelling.

What Factors Are Driving the Expansion of the Non-Invasive H. Pylori Testing Market?

The growth in the non-invasive Helicobacter pylori testing market is driven by several factors linked to technological innovation, healthcare delivery trends, changing patient preferences, and disease burden dynamics. At the technological level, rapid advancements in diagnostic platforms have led to more reliable and efficient breath and stool-based tests, making them suitable for widespread clinical and at-home use. These platforms are increasingly integrated with digital health tools, enabling result tracking, automated alerts, and seamless communication between patients and providers. On the clinical front, a growing preference for outpatient care and early diagnosis is motivating physicians to opt for non-invasive methods that minimize risk, streamline workflows, and accelerate treatment initiation. End-user demand is also being influenced by rising consumer awareness around gut health, foodborne pathogens, and the long-term risks of untreated infections. Patients, particularly in younger age groups and those with access to digital health resources, are actively seeking less invasive, more convenient testing options. In parallel, the increasing prevalence of H. pylori-driven by factors such as poor sanitation, antibiotic resistance, and changing dietary patterns-is fueling the need for scalable, cost-effective diagnostics across both developed and emerging markets. Healthcare systems under pressure to reduce costs and improve preventive care metrics are investing in screening programs that prioritize non-invasive solutions. Lastly, favorable regulatory landscapes and greater involvement from pharmaceutical companies-particularly those marketing antibiotics for eradication therapy-are encouraging widespread testing by bundling diagnostics with treatment protocols. These converging factors are ensuring strong, sustained growth in the non-invasive H. pylori testing market on a global scale.

SCOPE OF STUDY:

The report analyzes the Non-invasive Helicobacter Pylori Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Serologic Test, Urea Breath Test, Stool / Fecal Antigen Test); Method (Laboratory-based Test Method, Point of Care Test Method); End-Use (Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Biohit Oyj
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Certest Biotec S.L.
  • Coris Bioconcept SPRL
  • DiaSorin S.p.A.
  • Exalenz Bioscience Ltd.
  • Fujirebio Holdings, Inc.
  • Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Otsuka Holdings Co., Ltd.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Non-invasive Helicobacter Pylori Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Preference for Patient-Friendly Diagnostics Throws the Spotlight on Non-Invasive H. Pylori Testing Methods
    • Global Emphasis on Early Detection of Gastric Disorders Strengthens the Business Case for Non-Invasive Testing
    • Surge in Dyspepsia and Gastric Ulcer Cases Propels Growth Across Primary and Secondary Care Settings
    • Advancements in Urea Breath and Stool Antigen Tests Drive Accuracy and Broaden Clinical Adoption
    • Wider Integration into Preventive Health Check-Ups Expands the Addressable Market Opportunity
    • Government Screening Programs and Public Health Campaigns Accelerate Demand in High-Prevalence Regions
    • Shift Toward Decentralized and At-Home Testing Solutions Drives Adoption Among Convenience-Seeking Patients
    • Rise in Pediatric and Geriatric Gastrointestinal Care Spurs Demand for Gentler, Non-Invasive Test Options
    • Increased Awareness of H. Pylori's Role in Gastric Cancer Sustains Growth in Diagnostic Uptake
    • Healthcare Digitization and Lab Automation Strengthen Throughput and Efficiency of Non-Invasive Testing
    • Improved Sample Collection and Transport Technologies Drive Expansion in Remote and Low-Infrastructure Areas
    • Decline in Preference for Endoscopic Testing Creates Opportunities for Rapid, Low-Risk Alternatives
    • Pharmaceutical Alignment with Diagnostic Pathways Spurs Test-and-Treat Strategies Using Non-Invasive Methods
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-invasive Helicobacter Pylori Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Serologic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Serologic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Urea Breath Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Urea Breath Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Stool / Fecal Antigen Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Stool / Fecal Antigen Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Laboratory-based Test Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Laboratory-based Test Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Point of Care Test Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Point of Care Test Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION